Latest Conference Articles

Dr. Kapoor Discusses the Inclusion of Radium-223 in AUA Guidelines for CRPC

Deepak A. Kapoor, MD, from Integrated Medical Professionals, PLLC, discusses the inclusion of radium-223 in the AUA guideline for castration resistant prostate cancer (CRPC).

PSA Growth Rate May Help Identify Aggressive Prostate Cancer Early

Analysis of trends in prostate-specific antigen (PSA) dynamics suggested that PSA growth rates, as well as the amount of PSA-level increase due specifically to cancer, might offer a means of distinguishing aggressive, potentially fatal prostate cancer from clinically inconsequential tumors.

Dr. Evans Discusses the Subgroup Analysis Results of the PREVAIL Study

Christopher P. Evans, MD, professor, chairman, Department of Urology, University of California at Davis School of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of an analysis of patients with and without visceral disease defined as liver and/or lung metastases who participated in the PREVAIL study.

Intermittent Degarelix Effective With Less Metabolic Syndrome Than Hormone Agonists, Studies Suggest

Men given the GnRH antagonist degarelix because their PSA level rose after primary therapy fared at least as well on an intermittent medication schedule as on a continuous schedule

Cell-Cycle Gene Test Shows Early Promise in Clear Cell RCC

A cell-cycle gene array test demonstrated independent value for predicting metastatic progression after surgery for organ-confined renal cell carcinoma (RCC) of clear cell histology, a retrospective study of patient data showed.

Dr. Crawford on Intermittent Androgen Deprivation With Degarelix

E. David Crawford, MD, from University of Colorado at Denver, discusses a study presented at the 2014 AUA Annual Meeting that analyzed intermittent androgen deprivation with degarelix.

ED Therapy May Preserve Function, Penile Length After Prostatectomy

Daily treatment with the PDE-5 inhibitor tadalafil (Cialis) led to a significant decrease in loss of penile length among men who had undergone bilateral nerve-sparing radical prostatectomy.

Testicular Self-Examination Cost-Effective Compared with Missed Advanced Cancer

Testicular self-examination remains highly cost-effective despite a negative recommendation from the United States Preventive Services Task Force (USPSTF), a cost-utility analysis suggested.

In Dog Study, Prostate Cancer Found With a Whiff and a Woof

When it comes to detecting prostate cancer accurately and noninvasively, dogs may be ahead by a nose.

Dr. Aberger Discusses a Cost Analysis of Testicular Self-Examinations

Michael Aberger, MD, resident physician, University of Kansas Medical Center, discusses a cost analysis of testicular self-examinations.

Social Media Vital in Marketing Large Urology Practices

In the age of social media, simply having a website isn't enough. To keep existing patients and attract new ones, large urology group practices need to build websites that are connected to social media outlets at every turn, said Peter M. Knapp, Jr, MD.

Physical Activity Linked to Lower Risk of Death from Bladder Cancer

Self-reported physical activity significantly improved the odds that a person would not die of bladder cancer, a review of a national health information database showed.

Active Surveillance Is No Threat to Prostate Cancer Cure-So Far

Prostate cancer patients who chose active surveillance did not compromise their chances of a cure by waiting before they underwent radical prostatectomy, data from a Swedish registry showed.

Dr. Mirza on Hematuria and a Bladder Cancer Diagnosis

Moben Mirza, MD, assistant professor of urology at the University of Kansas Medical Center, discusses a study presented at the 2014 AUA Annual Meeting that evaluated gender and race variation in the workup of hematuria.

Dr. Rhee Discusses Workplace Violence in Urology Practices

Eugene Y. Rhee, MD, chief of urology, Kaiser Permanente, discusses workplace violence in urology practices.

As Lung Cancer Screening Debate Continues, Study Projects Implementation Outcomes

In December 2013, the US Preventive Services Task Force (USPSTF) recommended that asymptomatic, high-risk individuals receive annual screening for lung cancer with low-dose computed tomography (LDCT).

Novel TKI May Provide New Treatment Option for Patients With Recurrent PVNS

The new targeted drug, PLX3397, has demonstrated responses in patients with pigmented villonodular synovitis (PVNS), a rare joint disorder.

For Premenopausal Women With ER-Positive Disease, Obesity Is a Major Risk Factor in Breast Cancer Mortality

Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease.

Delaying ADT Until Symptoms Appear Does Not Impact Survival, Study Suggests

A rising prostate-specific antigen after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy.

AZD9291 Shows Robust Activity in Resistant EGFR-positive NSCLC

The highly selective EGFR inhibitor AZD9291 demonstrated an overall response rate of 64% without inducing dose-limiting toxicities in patients with metastatic NSCLC who harbor an acquired EGFR T790M resistance mutation.

Irregular Menstruation Linked to Higher Risk of Ovarian Cancer Death

A prospective study found that women with irregular menstrual cycles have a 2.4-fold increased risk of dying from ovarian cancer compared to women with normal menstrual cycles

PD-L1 Predictive of Response to MK-3475 in Melanoma and NSCLC

PD-L1 levels adequately predict response and clinical outcomes for PD-1 inhibitor MK-3475 in patients with non-small cell lung cancer (NSCLC) and melanoma

Dr. Flynn on CDK Inhibitors for the Treatment of CLL

Joseph M. Flynn, DO, MPH, FACP, co-director, Division of Hematology, associate physician-in-chief, OSUCCC - James, discusses cyclin-dependent kinase (CDK) inhibitors for the treatment of chronic lymphocytic leukemia (CLL).

David Lucas Discusses the Bromodomain Inhibitor OTX015

David Lucas, PhD, assistant professor, division of hematology, Ohio State University, discusses the bromodomain inhibitor OTX015.

I-SPY 2 Trial Graduates Neratinib for HER2-Positive Breast Cancer

The adaptive I-SPY 2 trial has found that a neoadjuvant regimen of neratinib and standard chemotherapy is beneficial for high-risk patients with hormone receptor (HR)-negative, HER2-positive stage II/III breast cancer

Palbociclib Dramatically Improves PFS in Updated Phase II Findings

The combination of palbociclib and letrozole more than doubled PFS and showed a non–statistically significant 4.2-month improvement in OS for patients with ER-positive, HER2-negative metastatic breast cancer.

CDK4/6 Inhibitor LY2835219 Shows Promise in Early Study

The CDK4/6 inhibitor LY2835219 demonstrated promising single-agent activity in heavily pretreated patients with HR-positive metastatic breast cancer.

Immunotherapies Promising But Still Challenging in CRPC

Increasing efficacy with immunotherapies in some cancers led to the strategy being deemed Breakthrough of the Year by Science magazine in 2013

Dr. Crawford on Rebiopsying for Prostate Cancer

E. David Crawford, MD, professor, Urologic and Radiation Oncology, head, Section of Urologic Oncology, University of Colorado at Denver, discusses rebiopsying for prostate cancer.

Continue Screening for PSA But Treat Judiciously

Screening for prostate-specific antigen (PSA) significantly cuts the death rate from prostate cancer, so America's medical community should continue to offer the test to appropriate men, but at the same time should work harder to avoid the screen's potential pitfalls.